*For medical professionals for reading reference
Recently, at the Bayer Show District of Shanghai International Convention and Exhibition Center, Academician Ge Junbo and Professor Zhou Jingmin from Starting from drug treatment, we will talk about many measures that help the incidence of cardiovascular events in my country.
Heart failure is a variety of causes that cause abnormal changes in the heart structure and (or) function, leading to obstacles of ventricular contraction and (or) diastolic function, which causes a group of complex clinical synthesisThe sign is a serious manifestation of cardiac diseases or advanced stages. The mortality rate and re -hospitalization rate remain high, and the disease burden is serious.With the deepening of clinical research, many heart failure treatment has been released in recent years.On November 6, 2024, at the main venue of Bayer, the Shanghai International Convention and Exhibition Center, Academician Ge Junbo and Professor Zhou Jingmin affiliated to Fudan University and Professor Zhou Jingmins breakthrough drugs, disease prevention and treatment of diseasesShare view.Some of the contents of this article hopes to benefit readers clinical practice.
The progress and challenge of heart failure treatment
As my country ages intensified, , high blood pressure and diabetes such as chronic diseases have increased, and the disease rate of heart failure in my country has continued to rise.According to statistics, the prevalence of heart failure in my country is 1.1%, and it is estimated that patients with heart failure at the age of 25 and above reached 12.5 million, and 2.97 million are added each year [1,2].Heart failure is the last battlefield of cardiovascular disease. Since the current mechanism of heart failure is not fully clarified, the effective prevention and control is still a huge challenge.Drug treatment is a very important part of heart failure diagnosis and treatment. Professor Zhou Jingmin said that although the treatment of heart failure in recent years has made great progress, some patients are still receiving β -blockers, aldehyde solid antagonists, blood vessels, blood vesselsTastein receptor encephalin enzyme inhibitors and sodium-glucose co-transport protein-2 inhibitors "New Four Union" treatment occur within one year, and even cardiovascular death occur within one year.This shows that in the field of heart failure drug treatment, we still face huge challenges and improvement space.
